Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2022-03-18 AGM Information
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
PR - PHARMANUTRA - Shareholder's Meeting documents
AGM Information Classification · 1% confidence The document is a short regulatory announcement (indicated by the header 'Informazione Regolamentata') dated March 18, 2022. The subject ('Oggetto') is 'PR - PHARMANUTRA - Shareholder's Meeting documents'. The text explicitly states that documents for the Shareholders' Meeting (which is scheduled for April 27th) are available at the registered office, on the company website, and in the authorized storage mechanism. It also mentions the appointment of a Designated Representative for voting. Since the document itself is an announcement stating that the actual meeting materials (like the Directors' Report) are available elsewhere, and it is short, it fits the definition of a Report Publication Announcement (RPA). It is not the full AGM presentation (AGM-R) or the proxy materials themselves (PSI), but the notice of their availability.
2022-03-18 English
CS - PHARMANUTRA - Documentazione Assemblea degli azionisti
AGM Information Classification · 1% confidence The document is an Italian regulatory announcement ("Informazione Regolamentata") with the subject line indicating 'CS - PHARMANUTRA - Documentazione Assemblea degli azionisti' (Shareholders' Meeting Documentation). The text explicitly states that documentation for the Shareholders' Meeting (Assemblea degli azionisti), including the Directors' Report, is available for consultation and mentions the date of the meeting (April 27, 2022). This content relates directly to materials prepared for the Annual General Meeting (AGM). Since the document itself is an announcement about the availability of AGM documentation, and not the presentation slides or the final voting results, it fits best under the category related to AGM information or the general announcement of related materials. Given the options, 'AGM-R' (AGM Information) is the most specific fit for documentation related to the AGM, even if this specific filing is the notice of availability. It is not a DEF 14A (Remuneration) or DVA (Voting Results). Because it is a short notice announcing the availability of AGM documents, it could potentially be RPA, but the core subject is the AGM documentation itself. I will classify it as AGM-R as it directly pertains to the AGM materials being made public.
2022-03-18 Italian
PR - PHARMANUTRA - Notice of call Shareholders' Meeting
AGM Information Classification · 1% confidence The document is explicitly titled "NOTICE CALLING THE ORDINARY GENERAL MEETING OF SHAREHOLDERS OF PHARMANUTRA S.P.A." and details the date, time, and agenda for the meeting, including items like financial statement approval, remuneration policy review, and appointment of auditors. The subject line also states "PR - PHARMANUTRA - Notice of call Shareholders' Meeting". This content directly relates to the formal announcement and logistics for an Annual General Meeting (AGM). Although it contains some financial reporting items on the agenda, the primary purpose of the document is the call notice itself, which aligns best with the AGM Information category (AGM-R). It is not the AGM presentation (AGM-R is for presentations/materials shared *during* the meeting), but the official call notice. However, given the options, AGM-R is the most specific fit for a document calling an AGM, as opposed to a general Regulatory Filing (RNS) or a Proxy Statement (PSI), although it contains elements of PSI. Since it is the formal call notice for the AGM, AGM-R is the intended classification for such preparatory documents in many filing taxonomies, or it could be considered a general regulatory announcement (RNS). Given the strong focus on the 'Shareholders' Meeting' call, AGM-R is selected as the primary type, representing the preparatory material for the AGM.
2022-03-18 English
CS - PHARMANUTRA - Avviso di convocazione Assemblea degli Azionisti
AGM Information Classification · 1% confidence The document is titled "AVVISO DI CONVOCAZIONE DI ASSEMBLEA ORDINARIA DI PHARMANUTRA S.P.A." (Notice of Call for Ordinary Shareholders' Meeting of PHARMANUTRA S.P.A.). It details the date, time, location, and the specific agenda items (ORDINE DEL GIORNO) for the upcoming shareholder meeting, including approval of the 2021 financial statements, remuneration policy, appointment of the Board of Statutory Auditors, and authorization for share buybacks. It also outlines the procedures for shareholder participation exclusively via a designated representative, as mandated by Italian COVID-19 related decrees. This content directly relates to the formal process and materials surrounding an Annual General Meeting (AGM). Therefore, the most appropriate classification is AGM-R (AGM Information).
2022-03-18 Italian
CS Pharmanutra - Approvazione progetto di Bilancio 2021
Earnings Release Classification · 1% confidence The document is an official communication from PHARMANUTRA S.P.A. regarding the approval of the 'Progetto di Bilancio di Esercizio e il Bilancio Consolidato al 31 dicembre 2021' (Draft Financial Statements and Consolidated Financial Statements as of December 31, 2021). It details significant financial results for the full year 2021, including Revenue, EBITDA, Net Income, and proposes a dividend. This content structure—full-year financial performance summary, management commentary, and detailed financial tables for the entire fiscal year—is characteristic of an Annual Report (10-K in the US context, or the primary annual filing in other jurisdictions). Although it is an announcement, the document itself contains the core financial data and analysis typically found in the full annual report, rather than just a brief notice of publication (RPA). Given the comprehensive nature of the financial review for the full year, it aligns best with the Annual Report category, even if it is presented as a press release summarizing the results. However, in many European contexts, the formal 'Bilancio di Esercizio' (Annual Financial Statements) is released separately from the comprehensive Management Discussion and Analysis (MDA) or the full statutory filing. Since this document is a press release announcing the *approval* of the draft statements and providing key highlights and commentary, it strongly overlaps with an Earnings Release (ER) or Management Report (MDA). Since it covers the *full year* and includes detailed financial tables and management discussion on strategy and results, it is more comprehensive than a standard quarterly ER. The closest fit among the provided codes for a comprehensive annual financial review announcement is the Annual Report (10-K), as it covers the entire fiscal year performance, but given the context of an Italian announcement of the *draft* statements, it functions as the primary disclosure of the annual results. Given the depth of financial data provided (Ricavi, Margine Operativo Lordo, Risultato Netto, PFN) and the focus on the full year 2021, it is classified as the Annual Report (10-K) equivalent disclosure. FY 2021
2022-03-18 Italian
Allegato 3F - Febbraio 2022
Director's Dealing Classification · 1% confidence The document is titled 'SCHEMA DI COMUNICAZIONE DELLE OPERAZIONI SUI TITOLI DELL'EMITTENTE' (Model Disclosure for Transactions in the Issuer's Securities) and specifically references Annex 3F, which is a standard Italian regulatory disclosure format for insider transactions. Section 1 identifies the issuer (PHARMANUTRA SPA). Section 2 identifies the party concluding the transactions (INTERMONTE SPA) and the security. Section 3 details daily transactions (purchases 'A' on the STAR segment of Borsa Italiana) occurring in February 2022. This structure precisely matches the requirements for reporting personal share transactions by directors or related parties, which corresponds to the 'Director's Dealing' category.
2022-03-08 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.